Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kymera Therapeutics, Inc. - Common Stock (NQ:KYMR)

111.36 +0.30 (+0.27%)
Streaming Delayed Price Updated: 11:50 AM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Kymera Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
JetBlue Airways, Pacira BioSciences And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded slightly higher, with the Nasdaq Composite gaining around 70 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
JPMorgan To Rally Around 17%? Here Are 10 Other Price Target Changes For Tuesday ↗
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Kymera Therapeutics ↗
 
Via Benzinga
Looking Into Kymera Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Where Kymera Therapeutics Stands With Analysts ↗
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
News headline image
5 Analysts Have This to Say About Kymera Therapeutics ↗
Analysts have provided the following ratings for Kymera Therapeutics (NASDAQ:KYMR) within the last quarter: 
Via Benzinga
News headline image
5 Analysts Have This to Say About Kymera Therapeutics ↗
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Recap: Kymera Therapeutics Q3 Earnings ↗
Kymera Therapeutics (NASDAQ:KYMR) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022 ↗
 
Via Benzinga
News headline image
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary ↗
 
Via Benzinga
News headline image
5 Analysts Have This to Say About Kymera Therapeutics ↗
  Within the last quarter, Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings: 
Via Benzinga
News headline image
Analyst Ratings for Kymera Therapeutics ↗
Kymera Therapeutics (NASDAQ:KYMR) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 8, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Kymera Gets Orphan Drug Status For Rare Blood Cancer Candidate ↗
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Kymera Therapeutics’ (NASDAQ: KYMR) product candidate KT-333 for the treatment of Cutaneous T-cell Lymphoma (CTCL). 
Via Benzinga
News headline image
Looking Into Kymera Therapeutics's Return On Capital Employed ↗
Kymera Therapeutics (NASDAQ:KYMR) brought in sales totaling $11.51 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 9.74%, resulting in a loss of $40.26... 
Via Benzinga
News headline image
Where Kymera Therapeutics Stands With Analysts ↗
Over the past 3 months, 6 analysts have published their opinion on Kymera Therapeutics (NASDAQ:KYMR) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Insiders Buying Ecolab, Kymera Therapeutics And This Consumer Cyclical Stock ↗
Although US stocks closed mostly lower on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Kymera Therapeutics Stock Scores Rising Relative Price Strength ↗
Kymera Therapeutics stock hit a key performance benchmark, with its Relative Strength Rating upgradedjulie mak to 94. 
Via Investor's Business Daily
News headline image
Kymera Therapeutics: Q2 Earnings Insights ↗
  Kymera Therapeutics (NASDAQ:KYMR) reported its Q2 earnings results on Tuesday, August 9, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 3, 2022 ↗
  
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For August 15, 2022 ↗
  
Via Benzinga
News headline image
Kymera Therapeutics Commences Initial-Stage Oncology Trials ↗
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has recently initiated dosing of patients in separate Phase 1 clinical trials evaluating its oncology drug candidates KT-333 and KT-413. 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Committee Backs Moderna Shot For 5-17 Years, 180 Life Sciences Stock Plunges, Pfizer's Posts Disappointing Paxlovid Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 20, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Why Kymera Therapeutics Stock Is Gaining Wednesday ↗
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Kymera Therapeutics (NASDAQ: KYMR) lead drug candidate KT-333 for the treatment of patients with Peripheral T-cell... 
Via Benzinga
News headline image
Fresh Del Monte Produce And 2 Other Stocks Insiders Are Buying ↗
Although the Dow Jones dropped more than 200 points on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
3 Biotech Stocks to Buy Before They Boom ↗
It could be a “never-before, never-after opportunity” to buy into these biotech stocks that trade at very attractive valuations. 
Via InvestorPlace
News headline image
Executives Buy Around $141M Of 4 Stocks ↗
Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades. 
Via Benzinga
News headline image
81 Biggest Movers From Yesterday ↗
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares climbed 62.4% to close at $2.16 on Wednesday after gaining around 5% on Tuesday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.